quantisnow
FeedTopReportsPricing
⌘K
Live feed
08:16:17·90d
ANALYSTRating
Arcturus Therapeutics Holdings Inc. logo

Roth Capital initiated coverage on Arcturus Therapeutics with a new price target

ARCT· Arcturus Therapeutics Holdings Inc.
Health Care
Original source

Companies

  • ARCT
    Arcturus Therapeutics Holdings Inc.
    Health Care

Recent analyst ratings

  • Mar 18UpdateB. Riley Securities$22.00
  • Jan 23UpdateRoth Capital$20.00
  • Oct 24UpdateH.C. Wainwright$12.00
  • Oct 23UpdateCitigroup$12.00
  • Oct 22UpdateGuggenheim-
  • Sep 4UpdateH.C. Wainwright$60.00

Related

  • PR3d
    When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech
  • SEC28d
    Amendment: SEC Form SCHEDULE 13G/A filed by Arcturus Therapeutics Holdings Inc.
  • ANALYST36d
    B. Riley Securities initiated coverage on Arcturus Therapeutics with a new price target
  • PR49d
    Arcturus Therapeutics to Attend Upcoming Investor Conference
  • SEC51d
    SEC Form 10-K filed by Arcturus Therapeutics Holdings Inc.
  • SEC51d
    Arcturus Therapeutics Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
  • PR51d
    Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Pipeline Progress
  • PR65d
    Arcturus Therapeutics to Report Fourth Quarter and Fiscal Year 2025 Financial Results and Provide Corporate Update on March 3, 2026
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022